RxDoctor Payments Data

Kemaya Wilburn

Psychiatric/Mental Health · Albany, GANPI 1841675667

Payments from drug & device makers

$1,347in general payments, 2019–2025

Across 57 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$371
  • Alkermes, Inc.$338
  • AbbVie$126
  • Teva Pharmaceuticals USA, Inc.$121
  • Neurocrine Biosciences, Inc.$81
  • E.r. Squibb & Sons, L.L.C.$81
  • plus $230 from 5 others

What the payments were for

  • Food & beverage$1,347100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,347 in reported general payments places this provider in the 75th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$1,658
Medicare patients
15
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PerserisRisperidone16$50,684
Abilify MaintenaAripiprazole11$32,034
Risperdal ConstaRisperidone Microspheres12$8,273
Fluphenazine Hcl14$1,599
Fluphenazine Decanoate15$1,540
Haloperidol Decanoate31$1,196
Divalproex Sodium ErDivalproex Sodium17$815
Buspirone Hcl22$461
Benztropine Mesylate41$412
Olanzapine24$248
Trazodone Hcl28$208
Escitalopram Oxalate19$198
Fluoxetine Hcl35$195
Risperidone18$178
Lorazepam12$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Perseris$371$50,68416 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$75$32,03411 claims
Johnson & JohnsonRisperdal Consta$34$8,27312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →